Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV003328463 | SCV001142217 | uncertain significance | CDH1-related diffuse gastric and lobular breast cancer syndrome | 2023-08-21 | reviewed by expert panel | curation | The c.363C>A variant is <1/50,000 alleles (0.002%, 2/113,262 alleles) in the non-Finnish European gnomAD subpopulation (PM2_Supporting; http://gnomad.broadinstitute.org). No additional evidence met criteria for consideration. Therefore, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting. |
Labcorp Genetics |
RCV000706606 | SCV000835669 | uncertain significance | Hereditary diffuse gastric adenocarcinoma | 2018-02-04 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glutamine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with CDH1-related disease. This variant is present in population databases (rs781427897, ExAC 0.003%). This sequence change replaces histidine with glutamine at codon 121 of the CDH1 protein (p.His121Gln). The histidine residue is moderately conserved and there is a small physicochemical difference between histidine and glutamine. |